BR112012024576A2 - composição farmacêutica de liberação modificada compreendendo desvenlafaxina ou sais da mesma e processo para preparação da dita composição - Google Patents
composição farmacêutica de liberação modificada compreendendo desvenlafaxina ou sais da mesma e processo para preparação da dita composiçãoInfo
- Publication number
- BR112012024576A2 BR112012024576A2 BR112012024576A BR112012024576A BR112012024576A2 BR 112012024576 A2 BR112012024576 A2 BR 112012024576A2 BR 112012024576 A BR112012024576 A BR 112012024576A BR 112012024576 A BR112012024576 A BR 112012024576A BR 112012024576 A2 BR112012024576 A2 BR 112012024576A2
- Authority
- BR
- Brazil
- Prior art keywords
- salts
- modified release
- desvenlafaxine
- composition
- preparing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
forma de dosagem de liberação modificada compreendendo desvenlafaxina ou sais da mesma. a presente invenção refere-se as composições faramacêuticas de liberação modificada compreendendo desvenilafaxina ou sais da mesma, um sistema modificador da taxa de liberação que controla a liberação de agente ativo em ambos os ambientes acídio e básico para fornecer liberação prolongada de ingrediente ativo , e opcionalmente um ou mais outro excipiente farmaceuticamente aceitável. a presente in venção tambpem se refere ao processo para preparação de tais composições e o método de usar tais composições. as composições farmacêuticas da presente invenão são úteis no provimento de níveis terapeuticamente eficazes de agente ativo durante período de tempo prolongado.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1099MU2010 | 2010-03-31 | ||
PCT/IB2011/051160 WO2011121475A2 (en) | 2010-03-31 | 2011-03-21 | Modified release dosage form comprising desvenlafaxine or salts thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012024576A2 true BR112012024576A2 (pt) | 2016-05-31 |
Family
ID=44511833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012024576A BR112012024576A2 (pt) | 2010-03-31 | 2011-03-21 | composição farmacêutica de liberação modificada compreendendo desvenlafaxina ou sais da mesma e processo para preparação da dita composição |
Country Status (6)
Country | Link |
---|---|
US (1) | US9408814B2 (pt) |
EP (1) | EP2552419A2 (pt) |
BR (1) | BR112012024576A2 (pt) |
CA (1) | CA2792352C (pt) |
MX (1) | MX2012010659A (pt) |
WO (1) | WO2011121475A2 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9230069B2 (en) | 2013-04-16 | 2016-01-05 | International Business Machines Corporation | Execution-based license discovery and optimization |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4535186A (en) | 1983-04-19 | 1985-08-13 | American Home Products Corporation | 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives |
US6274171B1 (en) | 1996-03-25 | 2001-08-14 | American Home Products Corporation | Extended release formulation of venlafaxine hydrochloride |
US6197828B1 (en) | 1998-12-01 | 2001-03-06 | Sepracor, Inc. | Derivatives of (+)-venlafaxine and methods of preparing and using the same |
ES2290281T5 (es) | 2001-02-12 | 2017-09-11 | Wyeth Llc | Sal de succinato de O-desmetil-venlafaxina |
US20050244498A1 (en) | 2001-09-14 | 2005-11-03 | Biovail Laboratories, Inc. | Modified-release compositions of at least one form of venlafaxine |
NZ537142A (en) | 2002-06-10 | 2008-01-31 | Wyeth Corp | Novel formate salt of O-desmethyl-venlafaxine |
JP2007520553A (ja) | 2004-02-06 | 2007-07-26 | ワイス | 多微粒子o−デスメチルベンラファキシン塩およびその使用 |
WO2006094083A1 (en) | 2005-02-28 | 2006-09-08 | Penwest Pharmaceuticals Co. | Controlled release venlafaxine formulations |
JP2008534592A (ja) | 2005-03-31 | 2008-08-28 | ワイス | O−デスメチルベンラファキシンおよびバゼドキシフェンの組み合わせ生成物およびその使用 |
WO2007011619A2 (en) | 2005-07-15 | 2007-01-25 | Wyeth | Highly bioavailable oral delayed release dosage forms of o-desmethylvenlafaxine succinate |
SG172660A1 (en) * | 2006-06-01 | 2011-07-28 | Schering Corp | Pharmaceutical compositions for sustained release of phenylephrine |
US20080220064A1 (en) * | 2006-12-06 | 2008-09-11 | Ramesh Ketkar Anant | Extended release matrix formulations of morphine |
US7820716B2 (en) | 2007-01-08 | 2010-10-26 | Mai De Ltd | Crystalline polymorphs of desvenlafaxine succinate and their preparations |
US20100330172A1 (en) | 2007-10-16 | 2010-12-30 | Alphapharm Pty Ltd | Controlled-release pharmaceutical formulation |
AU2007362336A1 (en) | 2007-12-10 | 2009-06-18 | Wyeth Llc | O-desmethyl-venlafaxine for treating major depressive disorder |
WO2009118763A1 (en) * | 2008-03-28 | 2009-10-01 | Panacea Biotec Limited | Multilayered pharmaceutical compositions and processes thereof |
EP2119696A1 (en) | 2008-05-16 | 2009-11-18 | Krka | Preparation of O-desmethylvenlafaxine salts |
EP2191822A1 (en) | 2008-11-26 | 2010-06-02 | LEK Pharmaceuticals d.d. | Controlled release pharmaceutical compositions comprising O-desmethyl-venlafaxine |
US20100209489A1 (en) | 2009-02-04 | 2010-08-19 | Supernus Pharmaceuticals, Inc. | Formulations of desvenlafaxine |
-
2011
- 2011-03-21 WO PCT/IB2011/051160 patent/WO2011121475A2/en active Application Filing
- 2011-03-21 CA CA2792352A patent/CA2792352C/en not_active Expired - Fee Related
- 2011-03-21 US US13/582,440 patent/US9408814B2/en not_active Expired - Fee Related
- 2011-03-21 MX MX2012010659A patent/MX2012010659A/es not_active Application Discontinuation
- 2011-03-21 EP EP11715747A patent/EP2552419A2/en not_active Withdrawn
- 2011-03-21 BR BR112012024576A patent/BR112012024576A2/pt not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
MX2012010659A (es) | 2013-03-05 |
CA2792352A1 (en) | 2011-10-06 |
WO2011121475A2 (en) | 2011-10-06 |
EP2552419A2 (en) | 2013-02-06 |
CA2792352C (en) | 2015-06-23 |
US20130059917A1 (en) | 2013-03-07 |
US9408814B2 (en) | 2016-08-09 |
WO2011121475A3 (en) | 2011-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201690102A1 (ru) | Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе | |
BR112013000920A2 (pt) | compostos para a redução de produção de beta-amiloide | |
BR112015022197A8 (pt) | uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia | |
EA201490228A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
BR112015000150A2 (pt) | composições farmacêuticas dissuasoras de abuso de liberação controlada | |
BR112015022972A2 (pt) | composição farmacêutica de cloridrato de s-cetamina | |
EA201491060A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
UY33183A (es) | Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento | |
BR112014031394A2 (pt) | composições e métodos para absorção transmucosa | |
BR112012026596A2 (pt) | método para preparar composições farmacêuticas pretendidas para administração oral compreendendo um ou mais ingredientes ativos e as composições que compreendem as mesmas | |
BR112015031878A2 (pt) | composição farmacêutica | |
BR112018012870A2 (pt) | métodos e composições para o tratamento de transtornos relacionados à crise | |
PE20140255A1 (es) | Tableta dispersable en forma oral | |
BR112015011430A2 (pt) | composição para liberação imediata e prolongada | |
NZ720328A (en) | Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease | |
BR112013021566A2 (pt) | composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula | |
EA201201202A1 (ru) | Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана | |
BR112015010271A8 (pt) | produto de comicronização, processo para o preparo de um produto de comicronização, composição farmacêutica e seus usos | |
WO2014016754A3 (en) | Pharmaceutical compositions of proton pump inhibitor | |
BR122020011180B8 (pt) | formulações injetáveis de compostos de tetraciclina | |
TN2014000031A1 (en) | Use of organic compound for the treatment of noonan syndrome | |
BR112012013918A2 (pt) | inibidores de diacil glicerol acil transferase | |
UY33723A (es) | ?COMPUESTOS Y SU USO PARA TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON Aß?. | |
GR1008228B (el) | Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου | |
BR112014016450A2 (pt) | composto antagonista de leucotrieno b4 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: dismissal - article 86 of industrial property law | ||
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |